Chronic ethanol consumption plus an atherogenic diet cause metabolic steatohepatitis with advanced liver fibrosis in apolipoprotein E/low-density lipoprotein receptor double-knockout mice.
EtOH
atherogenic diet
hyperlipidemia
metabolic steatohepatitis with advanced liver fibrosis
sympathetic activation
Journal
Alcoholism, clinical and experimental research
ISSN: 1530-0277
Titre abrégé: Alcohol Clin Exp Res
Pays: England
ID NLM: 7707242
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
15
04
2022
received:
25
10
2021
accepted:
25
04
2022
pubmed:
3
5
2022
medline:
9
8
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
Nonalcoholic steatohepatitis is the inflammatory subtype of nonalcoholic fatty liver disease with a high risk of progression to liver fibrosis. We investigated metabolic steatohepatitis with advanced liver fibrosis in apolipoprotein E/low-density lipoprotein receptor double-knockout (AL) mice fed a co-diet of ethanol with a low-carbohydrate-high-protein-high-fat atherogenic diet (AD) for 16 weeks. We also examined the underlying mechanisms, especially hepatic sympathetic activation, involved in the effects. We maintained 12-week-old male AL mice on AD and a standard chow diet (SCD) with or without ethanol treatment for 16 weeks. Age-matched male C57BL/6J mice on SCD without ethanol treatment served as controls. We conducted blood biochemical, histopathological, and fluorescence immunohistochemical, and reverse transcriptase polymerase chain reaction studies. AL mice showed significant hyperlipidemia. AD induced increased body weight, hepatic steatosis, and hepatic damage; ethanol and the AD co-diet resulted in hepatic sympathetic activation accompanied by hepatic steatosis, lobular inflammation, bridging fibrosis, and hepatic damage. Hepatic Kupffer cells (KCs) and hepatic stellate cells (HSCs), which showed sympathetic activation, produced 4.4- to 9.4-fold more inflammatory factors (KC and KC-derived tumor necrosis factor-α, and chemokine [C-C motif] ligand 2) and 2.0- to 32.0-fold more fibrosis factors (HSC and HSC-derived transforming growth factor β1 and collagen 1a1); all p < 0.05 vs. controls. We created a model of metabolic steatohepatitis with advanced liver fibrosis from coexisting hyperlipidemia and hepatic sympathetic activation in AL mice on a co-diet of ethanol and AD. KCs and HSCs became the cellular targets of hepatic sympathetic activation, which could play a role in the initiation and progression of metabolic steatohepatitis with advanced liver fibrosis.
Sections du résumé
BACKGROUND
Nonalcoholic steatohepatitis is the inflammatory subtype of nonalcoholic fatty liver disease with a high risk of progression to liver fibrosis. We investigated metabolic steatohepatitis with advanced liver fibrosis in apolipoprotein E/low-density lipoprotein receptor double-knockout (AL) mice fed a co-diet of ethanol with a low-carbohydrate-high-protein-high-fat atherogenic diet (AD) for 16 weeks. We also examined the underlying mechanisms, especially hepatic sympathetic activation, involved in the effects.
METHODS
We maintained 12-week-old male AL mice on AD and a standard chow diet (SCD) with or without ethanol treatment for 16 weeks. Age-matched male C57BL/6J mice on SCD without ethanol treatment served as controls. We conducted blood biochemical, histopathological, and fluorescence immunohistochemical, and reverse transcriptase polymerase chain reaction studies.
RESULTS
AL mice showed significant hyperlipidemia. AD induced increased body weight, hepatic steatosis, and hepatic damage; ethanol and the AD co-diet resulted in hepatic sympathetic activation accompanied by hepatic steatosis, lobular inflammation, bridging fibrosis, and hepatic damage. Hepatic Kupffer cells (KCs) and hepatic stellate cells (HSCs), which showed sympathetic activation, produced 4.4- to 9.4-fold more inflammatory factors (KC and KC-derived tumor necrosis factor-α, and chemokine [C-C motif] ligand 2) and 2.0- to 32.0-fold more fibrosis factors (HSC and HSC-derived transforming growth factor β1 and collagen 1a1); all p < 0.05 vs. controls.
CONCLUSIONS
We created a model of metabolic steatohepatitis with advanced liver fibrosis from coexisting hyperlipidemia and hepatic sympathetic activation in AL mice on a co-diet of ethanol and AD. KCs and HSCs became the cellular targets of hepatic sympathetic activation, which could play a role in the initiation and progression of metabolic steatohepatitis with advanced liver fibrosis.
Substances chimiques
Lipoproteins, LDL
0
Ethanol
3K9958V90M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1192-1203Informations de copyright
© 2022 by the Research Society on Alcoholism.
Références
Adams, L.A. (2019) End-points for drug treatment in NASH. Hepatology International, 13, 253-258.
Angulo, P. (2010) Long-term mortality in NAFLD: is liver histology of any prognostic significance? Hepatology, 51, 373-375.
Axley, P., Mudumbi, S., Sarker, S., Kuo, Y.F. & Singal, A.K. (2018) Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications. PLoS One, 13, e0197117.
de Castro, J.M. & Orozco, S. (1990) Moderate alcohol intake and spontaneous eating patterns of humans: evidence of unregulated supplementation. American Journal of Clinical Nutrition, 52, 246-253.
Chalasani, N., Younossi, Z., Lavine, J.E., Charlton, M., Cusi, K., Rinella, M. et al. (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67, 328-357.
Colditz, G.A., Giovannucci, E., Rimm, E.B., Stampfer, M.J., Rosner, B., Speizer, F.E. et al. (1991) Alcohol intake in relation to diet and obesity in women and men. American Journal of Clinical Nutrition, 54, 49-55.
Estes, C., Anstee, Q.M., Arias-Loste, M.T., Bantel, H., Bellentani, S., Caballeria, J. et al. (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. Journal of Hepatology, 69, 896-904.
Furuta, Y., Liu, J., Himemiya-Hakucho, A., Yoshimura, K. & Fujimiya, T. (2019) Alcohol consumption in combination with an atherogenic diet increased indices of atherosclerosis in apolipoprotein E/low-density lipoprotein receptor double-knockout mice. Alcoholism, Clinical and Experimental Research, 43, 227-242.
Gadd, V.L., Skoien, R., Powell, E.E., Fagan, K.J., Winterford, C., Horsfall, L. et al. (2014) The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology, 59, 1393-4105.
Hijona, E., Hijona, L., Arenas, J.I. & Bujanda, L. (2010) Inflammatory mediators of hepatic steatosis. Mediators of Inflammation, 2010, 837419.
Leoni, S., Tovoli, F., Napoli, L., Serio, I., Ferri, S. & Bolondi, L. (2018) Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World Journal of Gastroenterology, 24, 3361-3373.
Liang, W., Menke, A.L., Driessen, A., Koek, G.H., Lindeman, J.H., Stoop, R. et al. (2014) Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One, 9, e115922.
Liangpunsakul, S. & Chalasani, N. (2012) What should we recommend to our patients with NAFLD regarding alcohol use? American Journal of Gastroenterology, 107, 976-978.
Lin, Y.S., Nosaka, S., Amakata, Y. & Maeda, T. (1995) Comparative study of the mammalian liver innervation: an immunohistochemical study of protein gene product 9.5, dopamine beta-hydroxylase and tyrosine hydroxylase. Comparative Biochemistry and Physiology Part A, Physiology, 110, 289-298.
Liu, J. & Fujimiya, T. (2010) Abrupt termination of an ethanol regimen provokes ventricular arrhythmia and enhances susceptibility to the arrhythmogenic effects of epinephrine in rats. Alcoholism, Clinical and Experimental Research, 34(Suppl 1), S45-S53.
Liu, J., Takase, I., Hakucho, A., Okamura, N. & Fujimiya, T. (2012) Carvedilol attenuates the progression of alcohol fatty liver disease in rats. Alcoholism, Clinical and Experimental Research, 36, 1587-1599.
Marra, F. & Svegliati-Baroni, G. (2018) Lipotoxicity and the gut-liver axis in NASH pathogenesis. Journal of Hepatology, 68, 280-295.
Morrison, M.C., Verschuren, L., Kalic, K., Verheij, J., Menke, A., Wielinga, P.Y. et al. (2018) Obeticholic acid modulates serum metabolites and gene signatures characteristic of human NASH and attenuates inflammation and fibrosis progression in Ldlr-/-. Leiden mice. Hepatol Commun, 2, 1513-1532.
Neuschwander-Tetri, B.A. (2017) Non-alcoholic fatty liver disease. BMC Medicine, 15, 45.
Noto, H., Goto, A., Tsujimoto, T. & Noda, M. (2013) Low-carbohydrate diets and all-cause mortality: a systematic review and meta-analysis of observational studies. PLoS One, 8, e55030.
Oben, J.A. & Diehl, A.M. (2004) Sympathetic nervous system regulation of liver repair. The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology, 280, 874-883.
Oben, J.A., Roskams, T., Yang, S., Lin, H., Sinelli, N., Li, Z. et al. (2003) Norepinephrine induces hepatic fibro- genesis in leptin deficient ob/ob mice. Biochemical and Biophysical Research Communications, 308, 284-292.
Reimer, K.C., Wree, A., Roderburg, C. & Tacke, F. (2020) New drugs for NAFLD: lessons from basic models to the clinic. Hepatology International, 14, 8-23.
Sheka, A.C., Adeyi, O., Thompson, J., Hameed, B., Crawford, P.A. & Ikramuddin, S. (2020) Nonalcoholic steatohepatitis: a review. JAMA, 323, 1175-1183.
Weiskirchen, R., Weiskirchen, S. & Tacke, F. (2018) Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Research, 7, 921.
Wouters, K., van Gorp, P.J., Bieghs, V., Gijbels, M.J., Duimel, H., Lütjohann, D. et al. (2008) Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology, 48, 474-486.
Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. & Wymer, M. (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64, 73-84.
Zheng, F. & Cai, Y. (2019) Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet. Lipids in Health and Disease, 18, 6.